Brief Communication
The bat-borne influenza A virus H9N2 exhibits a set of unexpected pre-pandemic features
https://doi.org/10.21203/rs.3.rs-2937503/v1
This work is licensed under a CC BY 4.0 License
published 25 Apr, 2024
posted
You are reading this latest preprint version
An Old-World bat H9N2 influenza A virus (IAV) identified in Egypt exhibits high replication and transmission potential in ferrets, efficient infection of human lung explant cultures and marked escape from the antiviral activity of MxA. Together with low antigenic similarity to N2 of seasonal human strains, bat H9N2 meets key criteria for pre-pandemic IAVs.
Yes there is potential Competing Interest.
The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines, SARS-CoV-2 serological assays and SARS-CoV-2 vaccines which list Florian Krammer as co‐inventor. Viviana Simon is also listed as co-inventor on patent applications for SARS-CoV-2 serological assays. Mount Sinai has spun out companies, Kantaro and Castlevax, to market the SARS-CoV-2 related technologies. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus, 3rd Rock Ventures, GSK and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS‐CoV‐2 and with Dynavax on universal influenza virus vaccines. All other authors declare no competing interests.
published 25 Apr, 2024
posted
You are reading this latest preprint version